FDA Approves First At-Home Flu Vaccine, FluMist, Expanding Access for 2025-26 Season
Key Insights
The FDA has approved FluMist, the first influenza (search) vaccine for at-home use, administered as a nasal spray, for individuals aged 2-49 years.
This approval expands access to flu vaccination by allowing self-administration for adults up to 49 and caregiver administration for those aged 2-17 with a prescription.
Starting in the 2025-26 flu season, adults 18 and older can order FluMist online after completing an eligibility assessment, with pharmacist approval and direct shipment.
The U.S. Food and Drug Administration (FDA) has approved FluMist, the first influenza (search) (flu) vaccine for at-home use, marking a significant step in expanding access to flu prevention. Approved on September 20, 2024, this nasal spray vaccine offers a needle-free option for individuals aged 2 to 49 years, potentially increasing vaccination rates and reducing the burden of seasonal influenza.
FluMist: A Needle-Free Alternative
FluMist utilizes a weakened form of live influenza (search) virus strains A and B to stimulate a lasting immune response. Initially approved in 2003 for individuals aged 5 to 49, and later expanded to include children aged 2 to 5 in 2007, FluMist has been administered by medical providers in traditional healthcare settings. The new approval allows for self-administration by adults up to 49 years of age and administration by a caregiver for those between 2 and 17 years old.
Expanding Access Through At-Home Administration
The FDA anticipates that this convenient and flexible option will increase access to flu vaccination. Beginning in the 2025-26 flu season, individuals 18 years and older can order FluMist through a third-party online pharmacy via the FluMist website. After completing an eligibility assessment, a pharmacist will review and approve the order, and the vaccine will be shipped directly to the individual's home. A prescription is required for at-home use.
Impact on Public Health
Influenza (search) remains a significant public health concern, causing substantial morbidity and mortality each year. The CDC estimates that influenza has resulted in between 9 million and 41 million illnesses and between 140,000 and 710,000 hospitalizations annually in the United States over the past decade. By offering a more accessible and convenient vaccination option, FluMist has the potential to significantly reduce the impact of seasonal influenza, particularly among populations with limited access to traditional healthcare services.